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Abstract
Introduction: N-palmitoylethanolamine (PEA) is an endogenous fatty acid amide belonging to the family of the
N-acylethanolamines (NAEs). Recently, several studies demonstrated that PEA is an important analgesic, antiinflammatory,
and neuroprotective mediator. The aim of this study was to investigate the effect of co-ultramicronized PEA + luteolin
formulation on the modulation of the inflammatory response in mice subjected to collagen-induced arthritis (CIA).
Methods: CIA was induced by an intradermally injection of 100 μl of the emulsion (containing 100 μg of bovine
type II collagen (CII)) and complete Freund adjuvant (CFA) at the base of the tail. On day 21, a second injection of
CII in CFA was administered. Mice subjected to CIA were administered PEA (10 mg/kg 10% ethanol,
intraperitoneally (i.p.)) or co-ultramicronized PEA + luteolin (1 mg/kg, i.p.) every 24 hours, starting from day 25
to 35.
Results: Mice developed erosive hind-paw arthritis when immunized with CII in CFA. Macroscopic clinical evidence
of CIA first appeared as periarticular erythema and edema in the hindpaws. The incidence of CIA was 100% by day
28 in the CII-challenged mice, and the severity of CIA progressed over a 35-day period with a resorption of bone.
The histopathology of CIA included erosion of the cartilage at the joint. Treatment with PEA or PEA + luteolin
ameliorated the clinical signs at days 26 to 35 and improved histologic status in the joint and paw. The degree
of oxidative and nitrosative damage was significantly reduced in PEA + luteolin-treated mice, as indicated by
nitrotyrosine and malondialdehyde (MDA) levels. Plasma levels of the proinflammatory cytokines and chemokines
were significantly reduced by PEA + luteolin treatment.
Conclusions: We demonstrated that PEA co-ultramicronized with luteolin exerts an antiinflammatory effect during
chronic inflammation and ameliorates CIA.
Introduction
Rheumatoid arthritis (RA) is an autoimmune disease
that results in multiple joint inflammations with subse-
quent destruction of joint cartilage and erosion of bone.
Type II collagen-induced arthritis (CIA) in the mouse is
a useful model of RA, as it possesses many of the cell
and humoral immunity characteristics found in human
RA [1]. The pathogenesis of CIA is dependent on the
host’s response to type II collagen challenge and the
subsequent generation of antibodies that recognize
collagen-rich joint tissue [1]. Moreover, the recruitment
and activation of neutrophils, macrophages, and lym-
phocytes into joint tissues and the formation of the pan-
nus are hallmarks of the pathogenesis of both CIA and
human RA. Recently, it was demonstrated that interleukin
(IL)-8, MIP-lα, MIP-1β, and RANTES are differentially
chemotactic for lymphocyte subsets [2]. The current
treatments for delaying RA progression include several
disease-modifying antirheumatic drugs (DMARDs) and
biologic agents that act as immunomodulatory drugs
in RA [3], some also act by inhibiting cytokines and
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endothelial cell proliferation [4]. Moreover, all of these
compounds have potentially serious side effects; substan-
tial differences in toxicity occur among DMARDs [5].
N-palmitoylethanolamine (PEA) is an endogenous fatty
acid amide belonging to the family of the N-acylethanola-
mines (NAEs). PEA is an important analgesic, antiinflam-
matory, and neuroprotective mediator, acting at several
molecular targets in both central and sensory nervous sys-
tems as well as in immune cells [6]. Several mechanisms
have been proposed to explain the antiinflammatory and
antihyperalgesic effects of PEA, including: (a) the activa-
tion of a cell-surface receptor (that is, the “CBn” (or
CB2-like) or, alternatively, the orphan GPR55 receptor) or
otherwise a nuclear receptor of the peroxisome prolife-
rator-activated receptors (PPARs) family [7]; (b) the down-
modulation of mast cell hyperactivity (ALIA mechanism)
[8]; (c) an action as “entourage” compound (that is, the
augmentation of eCBs activities at their receptors and/or
the inhibition of eCBs degradation [9]). Although its pre-
sence in mammalian tissues has been known since the
1960s, PEA has emerged only recently among other bio-
active N-acylethanolamines as an important endogenous
lipid modulator that, because of its chemical stability, can
be also administered exogenously as the active principle of
current antiinflammatory and analgesic preparations [10].
Moreover, some evidence indicates that superoxide anions
(O2
-) perpetuate the chronic inflammatory state associ-
ated with RA. Thus, it follows that one therapeutic ap-
proach to treat RA is to remove these reactive oxygen
species (ROSs). Osteoclasts, chondrocytes, synovial cells
neutrophils/macrophages, and fragmented particles of de-
graded extracellular matrix are excellent sources of super-
oxide [11], as suggested from studies performed in animal
models of arthritis [12], as well as in pilot experiments
carried out in patients with active RA [13].
Flavonoids are natural products widely distributed in
the plant kingdom and currently consumed in large
amounts in the daily diet. Dietary flavonoids possess
multiple neuroprotective actions in central nervous patho-
physiologic conditions, including depression [14], and it
was reported that naringenin has potent antidepressant-
like properties through central serotonergic and nora-
drenergic systems. It was further suggested that dietary
flavonoids possess a therapeutic potential in disorders
especially in which the monoaminergic system is involved
[14]. Luteolin is a common flavonoid found in many types
of plants, such as Apium graveolens L. var. dulce [15],
Petroselium crispum [16], and Capsicum annuum L. var.
grossum [17]. It has various pharmacologic activities, such
as antioxidant and anticancer action [18].
The purpose of study was to determine whether pro-
longed administration of co-ultramicronized PEA + luteolin
(PEA-LUT) would ameliorate development of arthritis
by using a CIA model.
Methods
Animals
Male DBA/1J mice (9 weeks; Harlan Nossan, Italy) were
used for these studies. Mice were housed in individual
cages (two for each group) and maintained under a
12:12 light–dark cycle at 21°C ± 1°C and 50% ± 5% hu-
midity. The animals were acclimated to their environ-
ment for 1 week and had ad libitum access to tap water
and standard rodent diet. All animal experiments com-
plied with regulations in Italy (D.M. 116192), Europe
(O.J. of E.C. L 358/1 12/18/1986), and the United
States (Animal Welfare Assurance Number A5594-01,
Department of Health and Human Services, USA). All
behavioral testing was conducted in compliance with
the NIH laboratory animal care guidelines and with proto-
cols approved by the Institutional Animal Care and Use
Committee (Council directive 87–848, October 19, 1987,
Ministère de l’Agriculture et de la Forêt, Service Vétérinaire
de la Santé et de la Protection Animale, permission
92–256 to SC). The study was approved by the University
of Messina Review Board for the care of animals (PRIN ID
1042).
Experimental groups
Mice were divided into the following five experimental
groups:
CIA-Control: mice were subjected to collagen-induced
arthritis and administered 200 μl of 10% ethanol solution
(i.p., vehicle for PEA) every 24 hours, starting from day
25 to day 35 (n = 20).
CIA + LUT: mice subjected to collagen-induced arthritis
were administered LUT (1 mg/kg, 10% ethanol, i.p.)
every 24 hours, from day 25 to day 35 (n = 20).
CIA-PEA: mice subjected to collagen-induced arthritis
were administered PEA (10 mg/kg, 10% ethanol, i.p.)
every 24 hours, from day 25 to day 35 (n = 20).
CIA-PEA-LUT; mice subjected to collagen-induced
arthritis were administered PEA and luteolin (single
treatment combination) (1 mg/kg, i.p.) every 24 h,
starting from day 25 to day 35 (n = 20).
Sham-Control: mice subjected to an intradermal
injection at the base of the tail of 100 μl of 0.01 M
acetic acid, instead of the emulsion containing 100 μg
of CII, were treated with 200 μl of 10% ethanol solution
(i.p., vehicle for PEA), every 24 hours from day 25 to
day 35 (n = 20).
Sham-LUT: mice subjected to an intradermal injection
at the base of the tail of 100 μl of 0.01 M acetic acid
instead of the emulsion containing 100 μg of CII, were
administered LUT (1 mg/kg, 10% ethanol, i.p.), every
24 hours from day 25 to day 35 (n = 20).
Sham-PEA: mice subjected to an intradermal injection
at the base of the tail of 100 μl of 0.01 M acetic acid
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instead of the emulsion containing 100 μg of CII, were
administered PEA (10 mg/kg, 10% ethanol, i.p.), every
24 hours from day 25 to day 35 (n = 20).
Sham-PEA-LUT: mice subjected to an intradermal
injection at the base of the tail of 100 μl of 0.01 M acetic
acid instead of the emulsion containing 100 μg of CII,
were administered PEA and luteolin (single-treatment
combination) (1 mg/kg, i.p.), every 24 hours from day 25
to day 35 (n = 20).
PEA-LUT preparation was formulated through a co-
ultramicronization process by jet milling technology.
The ratio between PEA and luteolin is 10:1 by mass. The
doses of PEA and LUT were chosen based on our recent
studies [19,20] to compare possible differences with
PEA-LUT formulation.
Induction of CIA
The induction of CIA was performed as described in our
previous study [21]. Chicken type II collagen (CII) was
dissolved in 0.01 M acetic acid at a concentration of 2
mg/ml by stirring overnight at 4°C. Dissolved CII was
frozen at −70°C until use. Complete Freund adjuvant
(CFA) was prepared by the addition of Mycobacterium
tuberculosis H37Ra at a concentration of 2 mg/ml. Be-
fore injection, CII was emulsified with an equal volume
of CFA. On day 1, mice were injected intradermally at
the base of the tail with 100 μl of the emulsion (contai-
ning 100 μg of CII). On day 21, a second injection of CII
in CFA was administered.
Clinical assessment of CIA
The development of arthritis in mice in all experimental
groups was evaluated daily starting from day 20 after the
first intradermal injection by using a macroscopic sco-
ring system: 0 = no signs of arthritis; 1 = swelling and/or
redness of the paw or one digit; 2 = two joints involved;
3 =more than two joints involved; and 4 = severe arth-
ritis of the entire paw and digits [22]. Arthritic index for
each mouse was calculated by adding the four scores of
individual paws. Clinical severity was also determined by
quantitating the change in the paw volume by using
plethysmometry (model 7140; Ugo Basile).
Behavioral assays
Rotarod
Locomotor abilities were assessed with a protocol pre-
viously used [23]. DBA/1J mice were given 3 days of
training on the rotarod before disease induction. Trials
were conducted, starting on day 20 after CIA induction,
every 5 day until day 35. DBA/1J CIA mice treated with
vehicle, or PEA (10 mg/kg, i.p.), or PEA-LUT (1 mg/kg,
i.p.) were placed for 3 minutes on the rotating beam of a
rotarod (Ugo Basile) that was rotating at a fixed rate of
16 rpm. Each mouse was given three trials, after which
the average time that a mouse remained on the rotating
beam was calculated.
Pain-sensitivity testing
Hotplate testing was used to evaluate pain sensitivity as
previously described [24]. In brief, mice were placed on
a 55°C hotplate and observed by two individuals masked
to treatment. The latency to a behavioral response was
recorded. Behaviors included rearing, paw licking, paw
stamping, or jumping. Mice were removed from the hot-
plate after 30 seconds if no response was observed.
Thermal hyperalgesia
Hyperalgesic responses to heat were determined by the
Hargreaves Method by using a Basile Plantar Test (Ugo
Basile, Comeria, Italy) [25] with a cut-off latency of 20
seconds used to prevent tissue damage. Animals were
allowed to acclimate within a Plexiglas enclosure on a
clear glass plate in a quiet testing room. A mobile infrared
generator was positioned to deliver a thermal stimulus
directly to an individual hindpaw from beneath the cham-
ber. The withdrawal latency period of inflamed paws was
determined with an electronic-clock circuit and thermo-
couple. Foot-withdrawal latencies were taken on day 0 be-
fore CIA induction (baseline) and subsequently on days
25, 30, and 35 of the experimental period to determine the
analgesic effect of PEA or PEA-LUT treatments. A sig-
nificant (P < 0.05) reduction in paw-withdrawal latency
over time is characterized as thermal hyperalgesia. Data
obtained were converted to percentage maximal pos-
sible antinociceptive effect (%MPE) as follows: (response
latency − baseline latency)/(cut-off latency − baseline
latency) × 100.
Histologic examination
On day 35, animals were killed while they were under
anesthesia (sodium pentobarbital, 45 mg/kg, i.p), and
paws and knees were removed and fixed in 10% for-
malin. The paws were then trimmed, placed in decal-
cifying solution for 24 hours, embedded in paraffin,
sectioned at 5 μm, stained with hematoxylin/eosin, and
studied by using light microscopy (Dialux 22 Leitz). The
following morphologic criteria were considered: 0 = no
damage; 1 = edema; 2 = inflammatory cell presence; and
3 = bone resorption.
Staining of mast cells
Identification of mast cells was performed as described
in previous studies [26]. Paw sections were cut 5 μm
thick and stained with 0.25% toluidine blue, pH 2.5, for
45 minutes at room temperature. The sections were then
dehydrated and mounted in xylene-based medium for
viewing. Three nonsequential sections were chosen from
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one random block from each spinal cord for exami-
nation. All sections were evaluated at 200×, whereas
some sections were photographed at 400× by using a
Nikon inverted microscope.
Immunohistochemical localization of chymase, tryptase,
and nitrotyrosine
Immunohistologic analysis was performed as described in
previous studies [26]. On day 35, the joints were trimmed,
placed in decalcifying solution for 24 hours, and 8-μm sec-
tions were prepared from paraffin-embedded tissues. After
deparaffinization, endogenous peroxidase was quenched
with 0.3% H2O2 in 60% methanol for 30 minutes. The sec-
tions were permeabilized with 0.1% Triton X-100 in PBS
for 20 minutes. Nonspecific adsorption was minimized
by incubating the section in 2% normal goat serum in
phosphate-buffered saline for 20 minutes. Endogenous bio-
tin or avidin binding sites were blocked by sequential incu-
bation for 15 minutes with avidin and biotin. Sections were
incubated overnight with (a) anti-chymase antibody (1:100
in PBS, vol/vol) (DBA, Milan, Italy), (b) anti-tryptase anti-
body (1:500 in PBS, vol/vol), or (c) anti-nitrotyrosine rabbit
polyclonal antibody (1:1,000 in PBS, vol/vol). Controls in-
cluded buffer alone or nonspecific purified rabbit IgG. Sec-
tions were washed with PBS and incubated with secondary
antibody. Specific labeling was detected with a biotin- con-
jugated goat anti-rabbit IgG and avidin-biotin peroxidase
complex (Vector). To verify the binding specificity for chy-
mase and tryptase, some sections were also incubated with
only the primary antibody (no secondary) or with only the
secondary antibody (no primary). To confirm that the
immunoreaction for the nitrotyrosine was specific, some
sections were also incubated with the primary antibody
(anti-nitrotyrosine) in the presence of excess nitrotyrosine
(10 mM) to verify the binding specificity. In these situa-
tions, no positive staining was found in the sections, in-
dicating that the immunoreaction was positive in all the
experiments carried out. Immunocytochemistry photo-
graphs (n = 5) were assessed with densitometry by using
Optilab Graftek software on a Macintosh personal com-
puter [27].
Radiography
Radiography was performed as previously described [11].
The mice were anesthetized with sodium pentobarbital (45
mg/kg, i.p.). Mice were placed on a radiographic box at a
distance of 50 cm from the x-ray source. Radiographic ana-
lysis (Philips X12, Germany) of normal and arthritic mice
hindpaws was performed with a 40-kW exposure for 0.01
seconds. An investigator blinded to the treatment regimen
scored the radiographs. The following radiographic criteria
from hindlimbs were considered: score 0, no bone damage;
score 1, tissue swelling and edema; score 2, joint erosion;
and 3, bone erosion and osteophyte formation.
Measurement of cytokines
Tumor necrosis factor-α (TNF-α), interleukin (IL)-6, and
IL-1β levels were evaluated in the plasma from CIA and
sham mice, as previously described [28]. The assay was
carried out by using a colorimetric commercial ELISA
kit (Calbiochem-Novabiochem Corporation, Milan, Italy)
with a lower detection limit of 10 pg/ml.
Measurement of chemokines
Levels of chemokines MIP-1α and MIP-2 were measured
in the aqueous joint extracts. In brief, joint tissues were
prepared by first removing the skin and separating the
limb below the ankle joint. Joint tissues were homogenized
on ice in 3-ml lysis buffer (PBS containing 2 mM PMSF,
and 0.1 mg/ml (final concentration), each of aprotinin,
antipain, leupeptin, and pepstatin A) by using Polytron
(Brinkinarm Instruments, Westbury, NY, USA). The ho-
mogenized tissues were then centrifuged at 2,000 g for 10
minutes. Supernatants were sterilized with a millipore
filter (0.2 μm) and stored at −80°C until analyzed. The
extracts usually contained 0.2 to 1.5 mg protein/ml, as
measured with a protein-assay kit (Pierce Chemical Co.,
Rockford, IL, USA). The levels of MIP-1α and MIP-2 were
quantified by using a modification of a double-ligand me-
thod, as previously described [29]. In brief, flat-bottomed
96-well microtiter plates were coated with 50 μl/well of
rabbit anti-cytokine antibodies (1 μg/ml in 0.6 M NaCl,
0.26 m H3BO4, and 0.08N NaOH, pH 9.6) for 16 hours at
4°C, and then washed with PBS, pH 7.5, 0.05% Tween 20
(wash buffer). Nonspecific binding sites on microtiter
plates were blocked with 2% BSA in PBS and incubated
for 90 minutes at 37°C. Plates were rinsed 4 times with
wash buffer, and diluted aqueous joint samples (50 μl)
were added, followed by incubation for 1 hour at 37°C.
After washing of plates, chromogen substrate was added.
The plates were incubated at room temperature to the
desired extinction, after which the reaction was termi-
nated with 50 μl/well of 3 M H2SO4 solution. The plates
were then read at 490 nm in an ELISA reader. This
ELISA method consistently had a sensitivity limit of
about 30 pg/ml.
Thiobarbituric acid-reactant substances measurement
(MDA levels)
Thiobarbituric acid-reactant substances measurement,
which is considered a good indicator of lipid peroxi-
dation, was determined, as previously described [30].
Thiobarbituric acid-reactant substances were calculated
by comparison with OD650 of standard solutions of
1,1,3,3-tetramethoxypropan 99% malondialdehyde bis
(dymethyl acetal) 99% (MDA) (Sigma). The absorbance
of the supernatant was measured with spectrophoto-
metry at 650 nm.
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Myeloperoxidase (MPO) assay
Neutrophil infiltration into the inflamed joints was indi-
rectly determinate by using an MPO assay, as previously
described for neutrophil elicitation [31]. Tissue was
prepared as described earlier and placed in a 50 mM phos-
phate buffer (pH 6.0) with 5% hexadecyltrimethyl am-
monium bromide (Sigma Chemical). Joint tissues were
homogenized, sonicated, and centrifuged at 12,000 g for
15 minutes at 4°C. Supernatants were assayed for MPO
activity by using a spectrophotometric reaction with
O-dianisidine hydrochloride (Sigma Chemical) at 460 nm.
Materials
Unless otherwise stated, other compounds were obtained
from Sigma-Aldrich Company (Milan, Italy). All chemi-
cals were of the highest commercial grade available. All
stock solutions were prepared in nonpyrogenic saline
(0.9% NaCl; Baxter Healthcare Ltd., Thetford, Norfolk,
UK) or 10% ethanol (Sigma-Aldrich).
Data analysis
All values in the figures and text are expressed as mean ±
standard error (SEM) of the mean of n observations. For
the in vivo studies, n represents the number of animals
studied. In the experiments involving histology or immu-
nohistochemistry, the figures shown are representative of
at least three experiments (histologic or immunohisto-
chemistry coloration) performed on different experimental
days on the tissue sections collected from all the animals
in each group. Data sets were examined with one- or two-
way analysis of variance, and individual group means were
then compared with Student unpaired t test. For the
arthritis studies, Mann–Whitney U test (two-tailed, inde-
pendent) was used to compare medians of the arthritic
indices [22]. A P value of less than 0.05 was considered
significant.
Results
Effect of PEA-LUT formulation therapy in the development
of CIA
To imitate the clinical scenario of RA, mice were sub-
jected to CIA. CIA developed rapidly in mice immunized
with CII, and clinical signs (periarticular erythema and
edema) (Figure 1B) of the disease first appeared in hind-
paws between 24 and 26 days after challenge, leading to
a 100% incidence of CIA at day 28 (Figure 2B). Hindpaw
erythema and swelling increased in frequency and seve-
rity in a time-dependent mode, with maximum arthritis
indices of approximately 12 observed between days 29
and 35 after immunization (Figure 1L) in CIA-control
mice. The therapy with PEA-LUT significantly reduced
the development of the inflammatory process (Figure 1D
and L). A significant difference was found between the
treatment with PEA-LUT and the higher dose of PEA
alone (10 mg/kg) (Figure 1C and L), as well as between
the PEA-LUT and LUT-alone treatment (1 mg/kg) (data
not shown). Neither the clinical signs nor histopathologic
features of CIA were observed in the paws of sham con-
trols during the evaluation period (Figure 1A). PEA LUT
significantly reduced the arthritis index (Figure 2B). A
significant difference was found between the PEA-LUT
therapy and the higher dose of PEA alone (10 mg/kg)
(Figure 2B). No significant protection was found in the
animal subjected to CIA treated with LUT (1 mg/kg,
Figure 2B).
The data in Figure 2A demonstrate a time-dependent
increase in hindpaw (each value represents the mean
values of both hindpaws) volume (in milliliters) in mice
immunized with CII. Maximum paw volume occurred by
day 35 in the CII-immunized mice. Treatment with PEA-
LUT exhibited a continuously significant (P < 0.01) sup-
pression of hindpaw swelling from day 26 to 35 after
immunization, achieving a maximal response of 75% from
days 28 to 35 (Figure 2A). A significant difference was
found between the higher dose of PEA alone (10 mg/kg)
and the combination therapy (Figure 2A), as well as bet-
ween the PEA-LUT and LUT-alone treatment (1 mg/kg)
(Figure 2A). No significant inhibition of the paw-edema
formation was found in the animals subjected to CIA
treated with LUT (1 mg/kg, Figure 2A). No increases in
hindpaw volume over time were observed with normal
control (data not shown).
The rate and the absolute gain in body weight were
comparable in sham-control and in CIA-control mice in
the first week (data not shown). From day 25, the CII-
challenged mice gained significantly less weight than the
sham-control mice, and this trend continued through
day 35 (Figure 2C). PEA-LUT treatment determined a
significant increase of the body weight compared with
the vehicle treatment in CIA-control mice (Figure 2C).
A significant difference was found between the higher
dose of PEA alone (10 mg/kg) and the combination ther-
apy (Figure 2C), as well as between the PEA-LUT and
LUT-alone treatment (1 mg/kg, Figure 2C). The treat-
ment with LUT (1 mg/kg) did not exert any significant
effect on the body-weight gain in the animals subjected
to CIA (Figure 2C).
PEA-LUT formulation therapy increases motor activity in
CIA
In a previous study, we demonstrated that PEA-LUT
treatment is able to alleviate many of the clinical and neu-
ropathologic features of depression [32], but to our know-
ledge, PEA-LUT has not been investigated in this regard
in CIA. Therefore, we next assessed how prolonged daily
treatment with PEA-LUT affected the gross locomotor
ability, assessed by performance on a nonaccelerating
rotarod, in CIA mice. As shown in Figure 3A, PEA-LUT
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treatment significantly reduced the motor impairment in
CIA mice. Moreover, a significant difference on the motor-
function impairment was found between the PEA-LUT
therapy and the higher dose of PEA alone (10 mg/kg) and
between PEA-LUT therapy and LUT at a dose of 1 mg/kg
(Figure 3A). Treatment with LUT (1 mg/kg) did not sig-
nificantly ameliorate the locomotor ability in the animals
subjected to CIA (Figure 3A).
Effect of PEA-LUT formulation therapy on pain sensitivity
and thermal hyperalgesia in CIA
In the next step, the effect of PEA-LUT therapy on pain
sensitivity was tested by subjecting mice to hotplate
testing and recording latency to a response (Figure 3B). At
day 25 after CIA induction, CIA + vehicle mice exhibited
increased pain sensitivity compared with normal controls
(Figure 3B). Moreover, between days 30 and 35 after
immunization, PEA-LUT-treated mice with CIA had re-
sponse times that were comparable to normals (Figure 3B).
Furthermore, at day 25 after CIA induction, mice became
hypersensitive to noxious heat (thermal hyperalgesia), as
evidenced by a significant reduction in hindpaw with-
drawal latency, with a maximum hypersensitive response
observed between days 30 and 35 after immunization in
CIA-control mice (Figure 3C). This CIA-induced hyper-
algesia was reduced by daily treatment with PEA-LUT
Figure 1 Effect of PEA-LUT combination therapy on the clinical expression of CIA and on radiographic analysis. No clinical signs were
observed in sham mice (A). CIA developed rapidly in mice immunized with CII and clinical signs like periarticular erythema and edema (B). Hindpaw
erythema and swelling increased in frequency and severity in a time-dependent mode (L). CIA-PEA-treated mice demonstrated a significant reduction
in the clinical signs of CIA (C). Co-ultramicronized PEA + LUT formulation showed an enhanced reduction of clinical signs of CIA (D). In addition,
radiographic analysis was evaluated. No evidence of pathology in the femoral growth plate or in the tibiotarsal joints of normal mice (E, I). Hindpaws from
CII-immunized (35 days) vehicle-treated mice showed bone resorption in the femoral growth plate as well as in the tibiotarsal joints (F, I). PEA-treated mice
showed less bone erosion in the femoral growth plate, as well as in the tibiotarsal joints of CIA mice (G, I). A significant difference was showed between
PEA and PEA-LUT combination therapy as well as between PEA-LUT combination therapy and LUT-alone treatment (H, I). Figure is representative of at least
three experiments performed on different days. Values are expressed as mean ± SEM of 20 animals for each group. *P< 0.01 versus sham-control. °P< 0.01
versus CIA. #P< 0.01 versus CIA-PEA. §P< 0.01 versus CIA-LUT.
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(Figure 3C). Moreover, a significant difference on the pain-
sensitivity impairment was found between the PEA-LUT
therapy and the higher dose of PEA alone (10 mg/kg)
(Figure 3B, C), as well as between the PEA-LUT and LUT-
alone treatment (1 mg/kg, Figure 3B, C).
Effect of PEA-LUT formulation therapy on histopathology
and radiographic analysis of CIA
The histologic evaluation (at day 35) of the paws from
vehicle-treated mice revealed signs of severe arthritis,
with bone erosion (Figure 4A, A1, and see histologic
score I). In addition, severe or moderate necrosis was
observed (Figure 4A, A1, and see histologic score I). The
bone erosion and the necrosis were significantly reduced
in the joint from PEA-LUT-treated mice (Figure 4B, B1,
see for histologic score I). A significant difference was
found between the higher dose of PEA alone (10 mg/kg)
and the combination therapy, as well as between the
PEA-LUT and LUT-alone treatment (1 mg/kg, data not
shown). Treatment with LUT (1 mg/kg) did not reduce
the histologic alteration in the animals subjected to CIA
(data not shown). No histologic damage was found in
sham animals (data not shown).
A radiographic examination of knee joint and femoral
growth plate in the femur from vehicle-treated mice at
35 days after CII immunization revealed bone erosion
(Figure 1F; see radiograph score I). Significantly less
bone resorption was observed in the PEA-treated mice
(Figure 1G, and see radiograph score I). Treatment with
LUT (1 mg/kg) did not reduce significantly the bone re-
sorption in the animals subjected to CIA (data not
shown). A significant difference was found between the
higher dose of PEA alone (10 mg/kg) and the combination
therapy (Figure 1H, and see radiograph score I), as well as
Figure 2 Effect of PEA- LUT combination therapy on paw edema and body weight. CIA developed rapidly in mice immunized with CII, leading
to a 100% incidence of CIA at day 28 (B). Swelling of hindpaws (A) over time was measured at 2-day intervals. Beginning on day 25, the CII-challenged
mice gained significantly less weight, and this trend continued through day 35 (C). CIA-PEA mice demonstrated a significant reduced incidence of weight
loss (C), as well as less paw edema (A). CIA-LUT mice did not demonstrate a reduced incidence of weight loss (C) as well as less paw edema (A) compared
with the PEA group. Furthermore, the combination therapy with PEA and LUT enhanced the reduction of incidence of body-weight loss and paw
edema (A, C). Figure is representative of all the animals in each group. Values are expressed as mean ± SEM of 20 animals for each group. *P < 0.01
versus Sham-control. °P < 0.01 versus CIA. #P < 0.01 versus CIA-PEA. §P < 0.01 versus CIA-LUT.
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between the PEA-LUT and LUT-alone treatment (1 mg/kg,
data not shown). No evidence of pathology was found in
sham mice (Figure 1E, and see radiograph score I).
Effect of PEA-LUT formulation therapy on mast cells
degranulation during CIA
The better to study the mast cell infiltration during CIA,
the joint tissues were stained with toluidine blue. In par-
ticular, a significant presence of mast cells was observed
in the joint tissues collected at day 35 after CIA induc-
tion (Figure 4C), mainly localized in the articular space
(see particles 4 C1). On the contrary, significantly less
mast cell infiltration was observed in the joint tissues
from CIA-subjected mice that were been treated with
PEA-LUT (Figure 4D, D1). A significant difference was
found between the higher dose of PEA alone (10 mg/kg)
and the combination therapy, as well as between the
PEA-LUT and LUT-alone treatment (1 mg/kg, data not
shown). No resident mast cells were found in the joint
tissues from sham-treated mice (data not shown).
Moreover, to test whether PEA-LUT treatment may
modulate and direct the inflammatory response through
the regulation of the serine peptidases, we analyzed with
immunohistochemistry the joint expression of chymase
and tryptase. No staining for chymase and tryptase oc-
curred in the joint tissues obtained from the sham-treated
mice (data not shown). A substantial increase in chymase
and tryptase expression was found mainly localized in
mast cells in the joint tissues collected at 35 days after
CIA induction (Figure 4E, E1, G, G1, and see L). Joint
expression of chymase and tryptase was significantly
attenuated in the joints from CIA mice that received PEA-
LUT treatment (Figure 4F, F1, H, H1, and see L). A signifi-
cant difference was found between the higher dose of PEA
Figure 3 Effect of PEA- LUT combination therapy on locomotor activity and pain evaluation. CIA-subjected mice shortened the time to
stay on a rotating rod compared with sham mice (A). Locomotor abilities on the rotarod are better maintained in CIA + PEA than in CIA + Vehicle
mice (A). Locomotor abilities on the rotarod are not better maintained in CIA + LUT than on CIA + PEA mice (A). A significant difference in locomotor
activity was found between PEA and PEA-LUT combination therapy, as well as between PEA LUT combination therapy and LUT-alone treatment (A). In
addition, pain evaluation in CIA + vehicle, CIA-LUT, CIA + PEA, CIA + PEA-LUT, and sham mice was measured by a hotplate test and a plantar test.
Measurements were recorded in mice able to ambulate. CIA + vehicle mice exhibit increased pain sensitivity and thermal hyperalgesia compared with
normal controls. (B, C). PEA treatment reduced significantly pain sensitivity and thermal hyperalgesia in CIA-PEA-treated mice (B, C). LUT treatment did
not significantly reduce pain sensitivity and thermal hyperalgesia compared with the PEA group (B, C). The combination therapy with PEA-LUT
enhanced the reduction of pain sensitivity and thermal hyperalgesia compared with a higher dose of PEA (B, C). Figure is representative of all the
animals in each group. Values are given as mean ± SEM of 20 animals for each group. *P < 0.01 versus Sham-control. °P < 0.01 versus CIA. #P < 0.01
versus CIA-PEA. §P < 0.01 versus CIA-LUT.
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alone (10 mg/kg) and the combination therapy, as well as
between the PEA-LUT and LUT-alone treatment (1 mg/kg,
data not shown).
Effect of PEA-LUT formulation therapy on cytokines,
chemokines expression, and neutrophil infiltration
We initiated studies to assess the effect of PEA-LUT the-
rapy on the expression of chemokines into the inflamed
joints during the development of CIA. As shown in
Figure 5A, B, the expression of MIP-lα and MIP-2, mea-
sured with ELISA, was significantly increased in the joint
35 days after CII immunization. MIP-1α and MIP-2 levels
in CIA mice that were treated with PEA-LUT on day 35
were significantly reduced in comparison with vehicle-
treated CIA mice (Figure 5A, B). Assessment of neutrophil
infiltration into the inflamed joint tissue was also per-
formed by measuring MPO activity. It was significantly
elevated 35 days after CII immunization in vehicle-treated
CIA mice (Figure 5F), whereas in the CIA mice treated
with PEA-LUT therapy, MPO activity was markedly re-
duced (Figure 5F). A significant difference was found bet-
ween the higher dose of PEA alone (10 mg/kg) and the
combination therapy, as well as between the PEA-LUT
and LUT-alone treatment (1 mg/kg, Figure 5A, B, F).
To test whether PEA-LUT modulates the inflammatory
process through the regulation of cytokine secretion, we
analyzed the plasma levels of the proinflammatory cyto-
kines TNF-α, IL-1β, and IL-6. A substantial increase in
TNF-α, IL-1β, and IL-6 (Figure 5C, D, E) production
was found in CIA-control mice 35 days after CII im-
munization. Levels of TNF-α, IL-1β, and IL-6 (Figure 5C,
D, E) were significantly reduced in CIA mice treated with
PEA-LUT therapy. No significant difference was found
between the higher dose of PEA alone (10 mg/kg) and the
Figure 4 Morphologic changes of CIA. Representative hematoxylin/eosin-stained section of the joint was examined with light microscopy. The
histologic evaluation of a joint from CIA-control mice (A, A1, and I) revealed inflammatory cell infiltration and bone erosion. The histologic alterations
were significantly reduced in the tissues from CIA-PEA-LUT treated mice (B, B1, and I). Toluidine blue staining was also performed. A significant mast
cell infiltration was observed in joint tissues of CIA-subjected mice (C, C1) compared with sham animals (data not shown). PEA-LUT enhanced the
reduction of mast cell infiltration (D, D1). In addition, a significant increase in chymase and tryptase expression was found mainly in the joint tissues
collected after CIA induction (E, E1, G, G1, and L). Chymase and tryptase expression was significantly attenuated in the joint from CIA-PEA-LUT-treated
mice (F, F1, H, H1, and see L). Densitometry analysis of immunocytochemistry photographs (n = 5) for chymase and tryptase from paw sections was
assessed (L). Data are expressed as percentage of total tissue area. *P < 0.01 versus Sham-control. °P < 0.01 versus CIA. #P < 0.01 versus CIA-PEA.
§P < 0.01 versus CIA-LUT.
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combination therapy, as well as between the PEA-LUT and
LUT-alone treatment (1 mg/kg, Figure 5C, D, E).
Effect of PEA-LUT formulation therapy on nitrotyrosine
formation and lipid peroxidation
The release of free radicals and oxidant molecules du-
ring chronic inflammation has been suggested to con-
tribute significantly to the tissue injury [33]. On day 35,
a positive staining for nitrotyrosine, a marker of nitrosa-
tive injury, was found in the joints of vehicle-treated
CIA-control mice (Figure 6A, A1, and see C). The the-
rapy with PEA-LUT significantly reduced the formation
of nitrotyrosine (Figure 6B, B1, and see C). A significant
difference was found between the higher dose of PEA
alone (10 mg/kg) and the combination therapy, as well
as between the PEA-LUT and LUT-alone treatment
(1 mg/kg, data not shown).
In addition, at 35 days after CIA induction, thiobarbituric
acid-reactant substance levels were measured in the plasma
as an indicator of lipid peroxidation. A significant increase
of thiobarbituric acid-reactant substances (Figure 6D) was
observed in the plasma collected at 35 days after CIA in-
duction from mice subjected to CIA when compared
with sham-operated mice. Thiobarbituric acid-reactant
substances (Figure 6D) were significantly attenuated in
CIA-mice treated with PEA-LUT. Please note that a
significant difference was found between the higher dose
of PEA alone (10 mg/kg) and the combination therapy
(Figure 6D), as well as between the PEA-LUT and LUT-
alone treatment (1 mg/kg, Figure 6D).
Discussion
ROSs have a crucial role in the pathogenesis of inflam-
matory diseases such as rheumatoid arthritis [34,35].
Figure 5 Effect of PEA-LUT combination therapy on cytokines, chemokine expression, and neutrophil infiltration. A substantial increase
in the expression of MIP-1α (A), MIP-2 (B), IL-1β (C), IL-6 (D), TNF-α (E), and MPO activity (F) was found in CIA-control mice 35 days after CII
immunization. CIA-PEA-treated mice demonstrated a significant reduction in the expression of MIP-1α (A), MIP-2 (B), IL-1β (C), IL-6 (D), TNF-α (E),
and MPO activity (F). CIA-LUT-treated mice did not significantly reduce the expression of MIP-1α (A), MIP-2 (B), IL-1β (C), IL-6 (D), TNF-α (E), and
MPO activity (F). The combination therapy with PEA-LUT significantly reduced the expression of MIP-1α (A), MIP-2 (B), IL-1β (C), IL-6 (D), TNF-α
(E), and MPO activity (F). Values are shown as mean ± SEM of 20 animals for each group. *P < 0.01 versus Sham-control. °P < 0.01 versus CIA-control.
#P < 0.01 versus CIA-PEA. §P < 0.01 versus CIA-LUT.
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The flavonoid, apigenin, which has a structure similar to
that of luteolin, showed an antidepressant-like effect [36]
and a protective effect against endoplasmic stress-induced
neuronal cell death [36]. These findings suggest the possi-
bility that luteolin may be protective against oxidative
stress-induced inflammation and cell damage. With this
aim in mind, we applied the endocannabinoid congener
PEA and the flavonoid luteolin to counteract the in-
flammatory process associated with RA. Our results
demonstrated that co-ultramicronized PEA + luteolin for-
mulation (PEA-LUT) is protective in a mouse model of
collagen-induced arthritis. The protective effects of PEA-
LUT were not limited to an overall antiinflammatory
effect, but included significant protection of cartilage/bone
compared with that in untreated collagen-immunized ani-
mals, as well as inhibition of proinflammatory cytokines
known to be involved in the human disease. Through both
histologic and radiographic evaluations, we found that
PEA-LUT was significantly protective on the cartilage and
bone in tibiotarsal joints of mice immunized with CII.
PEA has been shown to be effective in several experi-
mental models of inflammation, of both immunogenic
and neurogenic origin [37,38]. We recently demonstrated
that PEA treatment significantly reduced spinal cord in-
jury in mice [39]. Despite its various pharmacologic pro-
perties, the cellular/receptor mechanism responsible for
the actions of PEA is still debated. Mazzari et al. [37]
demonstrated that in vivo antiinflammatory effects of PEA
were due to downregulation of mast cell (MC) degranu-
lation. The ability of MCs to respond to a wide range of
infectious and chemical stimuli facilitates their key func-
tions in immunity and the response to tissue injury, by
promoting a rapid release of proinflammatory mediators,
mediators of hyperalgesia, and itch mediators [40]. MCs
were divided into two subtypes, depending on the variable
content of the neutral serine proteases, tryptase and
Figure 6 Effect of PEA-LUT combination therapy on nitrotyrosine immunostaining and MDA levels. A marked increase in nitrotyrosine
(A, see particularly A1 and C), staining was evident in the paw 35 days after initiation of CIA. A marked reduction was seen in the immunostaining for
nitrotyrosine (B, see particularly B1 and C) in the paws of CIA-PEA-LUT mice. Densitometry analysis of immunocytochemistry photographs (n = 5) for
nitrotyrosine from paw sections was assessed (C). The assay was carried out by using Optilab Graftek software on a Macintosh personal computer
(CPU G3-266). Data are expressed as percentage of total tissue area. *P < 0.01 versus Sham-control. °P < 0.01 versus CIA. In addition, MDA levels, a
marker of lipid peroxidation, were evaluated. A substantial increase in MDA levels (D) was found in CIA-control mice 35 days after CII immunization.
CIA-PEA-treated mice demonstrated a significant reduction in MDA levels (D). The combination therapy with PEA-LUT enhanced the reduction in MDA
levels (D). Values are given as mean ± SEM of 20 animals for each group. *P < 0.01 versus Sham-control. °P < 0.01 versus CIA-control. #P < 0.01 versus
CIA-PEA. §P < 0.01 versus CIA-LUT.
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chymase. We report here that CIA caused a significant in-
filtration and activation of MCs in the joint at 35 days
after induction, whereas treatment with PEA-LUT signi-
ficantly reduced both the infiltration and the activation.
These observations are in agreement with other studies,
which have shown that PEA is an effective tool to control
mast cell hyperactivity, which occurs in inflammation, in-
flammatory hyperalgesia [41], neuropathic hyperalgesia
[42], and spinal and brain trauma [19,26]. It has been
demonstrated that several cytokines also appear to direct
cell-to-cell communication in a cascade fashion during
CIA, such as: IL-1 [43], TNF-α [44], and IL-6 [45]. TNF-α
and IL-1β are initiators of the nuclear factor (NF-κB) ac-
tivation cascade [34] and are under its transcriptional
control, constituting a positive-feedback loop. Recent
studies observed that the luteolin or PEA decreased the
activation of the NF-κB system in different experimental
models [46,47].
We confirmed that the proinflammatory cytokines
(IL-1β, IL-6, and TNF-α), as well as the chemokines (MIP-
Iα and MIP-2), are expressed at sites of inflamed joints
and likely contribute to the progression of chronic joint
inflammation. It has been demonstrated that MCP-1,
MIP- Iα, and MIP-Iβ are differentially chemotactic for
lymphocyte subsets [2] and are expressed in tissue from
the inflamed joints of patients with rheumatoid arthritis
[48,49]. Interestingly, by using PEA-LUT, we demon-
strated a more pronounced inhibition of the release of
proinflammatory cytokines and chemokines and a reduc-
tion of leukocyte infiltration measured by MPO activity in
comparison with PEA alone.
The role of ROSs and, in particular, of superoxide in
degradation of cartilage and bone is well documented
[11,50]. Cartilage is sensitive to degradation by supe-
roxide, and SOD strongly inhibits this degradation; evi-
dence exists to support a link between chondrocyte lipid
peroxidation and cartilage oxidation/degradation [11]. In
this report, an intense immunostaining of nitrotyrosine
formation and a significant lipid peroxidation also sug-
gested that a structural alteration of joint had occurred,
most probably because of the formation of highly reac-
tive nitrogen derivatives.
We demonstrated here that PEA-LUT reduced the
nitrotyrosine and the lipid peroxidation formation du-
ring CIA. Several studies demonstrated that luteolin also
exerts antioxidant properties [51]. This effect on nitro-
tyrosine formation and lipid peroxidation by PEA-LUT
was significantly more pronounced in comparison with
PEA alone.
In previous studies, we demonstrated that combination
therapy by using a potent M40403 SODm and clinically
used drugs (for example, dexamethasone or methotrexate)
significantly exerts an important beneficial antiinflam-
matory effect by blocking the possible progression of an
emerging arthritis with the reduction of a DMARS effec-
tive dose [11]. Similarly, in the present study, we demon-
strated that PEA-LUT, when given at the onset of the
disease, reduced paw swelling, the clinical score, and the
histologic severity. Amelioration of joint disease was asso-
ciated with inhibition of pain, which is a key player in RA.
Thus, these potent analgesic and antiinflammatory effects
observed with PEA-LUT were in contrast to those ob-
served with the individual substances administered at
lower doses (data not shown).
Conclusions
RA is a complex chronic inflammatory disease dependent
on multiple interacting environmental and genetic factors,
making it difficult to understand its pathogenesis and
thereby to find effective therapies. This new pharmaco-
logic approach with PEA-LUT combination therapy may
represent new and useful pharmacologic tools for the
therapy for chronic inflammation.
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